CD274 and ovarian carcinoma: Freig et al reported in a trial of an anti-programmed death ligand 1 (PD-L1) antibody that objective responses were reported in malignant melanoma, renal-cell cancer, non-small cell lung cancer (NSCLC) and ovarian cancer, but there were no responders among the 14 patients with advanced PDACs [38, 44].